



ZIOPHARM Oncology, Inc.  
 Investor Relations Department  
 One First Ave., Parris Building, # 34  
 Navy Yard Plaza  
 Boston, MA 02199  
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: ZIOP**

Last Trade:	4.44
Trade Time:	4:00 PM ET Dec 13, 2017
Change:	0.27 (+6.475%)
Day Range	4.15 - 4.48
52-Week Range	3.90 - 7.88
Volume	1,571,220


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Dec 10, 2017*  
[ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting](#)
- Nov 20, 2017*  
[ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting](#)
- Nov 17, 2017*  
[ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)
- Nov 10, 2017*  
[ZIOPHARM to Present at the Stifel 2017 Healthcare Conference](#)
- Nov 6, 2017*  
[ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities](#)

**Financials** [\[ View all \]](#)

- Feb 16, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 31, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)